Int J Stomatol

Int J Stomatol ›› 2022, Vol. 49 ›› Issue (5): 614-620.doi: 10.7518/gjkq.2022064

• Reviews • Previous Articles    

Research progress on immune checkpoint inhibitor combined with radiotherapy in head and neck squamous cell carcinoma

Li Hongfang(),Chen Zhong(),Zhang Suxin.   

  1. Dept. of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
  • Received:2022-01-05 Revised:2022-05-02 Online:2022-09-01 Published:2022-09-16
  • Contact: Zhong Chen E-mail:1048714296@qq.com;chenzhong8358@sina.com
  • Supported by:
    Key Science and Technology Research Program of Hebei Provincial Health Commission(20190695)

RichHTML

18

PDF (PC)

670

Abstract:

Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor. Most patients with HNSCC are in the advanced stage when they are diagnosed. Traditional treatment methods for HNSCC are limited, and the recurrence rate is more than 50%. The development of immunotherapy based on immune checkpoint inhibitors (ICIs) has brought a new option for HNSCC patients. ICIs can kill tumor cells or inhibit the development of tumors by activating or enhancing the antitumor immune function of the body. However, the effectiveness of ICI drug therapy alone is very limited, and only some patients can benefit. Radiotherapy (RT) is one of the traditional treatments for HNSCC. RT can induces immune-mediated antitumor responses by directly killing tumor cells and promoting tumor antigen presentation. ICI has synergistic antitumor effect with radiotherapy, and the combination of ICI and radiotherapy can improve the antitumor immune effect. ICI has synergistic antitumor effect with radiotherapy, and the combination of ICI and radiotherapy can improve the antitumor immune effect. This review summarizes the mechanisms of action and clinical progress of ICI, and the related progress of ICIs combined with RT in HNSCC.

Key words: head and neck squamous cell carcinoma, immune checkpoint inhibitor, radiotherapy, combination the-rapy

CLC Number: 

  • R 782

TrendMD: 
1 Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2 Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment[J]. Mayo Clin Proc, 2016, 91(3): 386-396.
3 Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer[J]. Lancet, 2008, 371(9625):1695-1709.
4 Morisada M, Chamberlin M, Allen C. Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer[J]. Head Neck, 2018, 40(6): 1321-1334.
5 Sharma P, Allison JP. The future of immune checkpoint therapy[J]. Science, 2015, 348(6230): 56-61.
6 Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition[J]. Am J Clin Oncol, 2016, 39(1): 98-106.
7 Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy[J]. Ann Oncol, 2018, 29(1): 71-83.
8 崔佳宁, 王俊杰. 免疫治疗联合放疗治疗晚期非小细胞肺癌的进展[J]. 现代肿瘤医学, 2018, 26(15): 2477-2480.
Cui JN, Wang JJ. Progress of immunotherapy combined with radiotherapy for advanced non-small cell lung cancer[J]. J Mod Oncol, 2018, 26(15): 2477-2480.
9 Collins AV, Brodie DW, Gilbert RJ, et al. The interaction properties of costimulatory molecules revisited[J]. Immunity, 2002, 17(2): 201-210.
10 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264.
11 Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma[J]. N Engl J Med, 2013, 369(2): 122-133.
12 Deng WW, Wu L, Sun ZJ. Co-inhibitory immune checkpoints in head and neck squamous cell carcinoma[J]. Oral Dis, 2018, 24(1/2): 120-123.
13 Siu LL, Even C, Mesía R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial[J]. JAMA Oncol, 2019, 5(2): 195-203.
14 Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma[J]. Cancer Res, 2013, 73(6): 1733-1741.
15 Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26: 677-704.
16 Bennett F, Luxenberg D, Ling V, et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses[J]. J Immunol, 2003, 170(2): 711-718.
17 Yang B, Liu TJ, Qu Y, et al. Progresses and perspectives of anti-PD-1/PD-L1 antibody therapy in head and neck cancers[J]. Front Oncol, 2018, 8: 563.
18 Ferris RL, Blumenschein G Jr, Fayette J, et al. Ni-volumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19): 1856-1867.
19 Ferris RL, Blumenschein G Jr, Fayette J, et al. Ni-volumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol, 2018, 81: 45-51.
20 Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)[J]. J Immunother Cancer, 2019, 7(1): 184.
21 Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012[J]. Br J Cancer, 2018, 119(2): 153-159.
22 Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7): 956-965.
23 Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase Ⅱ study[J]. J Clin Oncol, 2017, 35(14): 1542-1549.
24 Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 393(10167): 156-167.
25 Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928.
26 Segal NH, Ou SI, Balmanoukian A, et al. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: Results from a phase Ⅰ/Ⅱ expansion cohort[J]. Eur J Cancer, 2019, 109: 154-161.
27 Colevas AD, Bahleda R, Braiteh F, et al. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase Ⅰ trial[J]. Ann Oncol, 2018, 29(11): 2247-2253.
28 Wang YF, Liu ZG, Yuan HF, et al. The reciprocity between radiotherapy and cancer immunotherapy[J]. Clin Cancer Res, 2019, 25(6): 1709-1717.
29 Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class Ⅰ expression, and induces successful antitumor immunotherapy[J]. J Exp Med, 2006, 203(5): 1259-1271.
30 Manukian G, Bar-Ad V, Lu B, et al. Combining radiation and immune checkpoint blockade in the treatment of head and neck squamous cell carcinoma[J]. Front Oncol, 2019, 9: 122.
31 Park SS, Dong HD, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect[J]. Cancer Immunol Res, 2015, 3(6): 610-619.
32 Rodriguez-Ruiz ME, Rodriguez I, Garasa S, et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming[J]. Cancer Res, 2016, 76(20): 5994-6005.
33 Young KH, Baird JR, Savage T, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy[J]. PLoS One, 2016, 11(6): e0157164.
34 Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment[J]. Int J Radiat Oncol Biol Phys, 2015, 92(2): 368-375.
35 Choi JS, Sansoni ER, Lovin BD, et al. Abscopal effect following immunotherapy and combined stereotactic body radiation therapy in recurrent metastatic head and neck squamous cell carcinoma: a report of two cases and literature review[J]. Ann Otol Rhinol Laryngol, 2020, 129(5): 517-522.
36 Wu JS, Jen CW, Chen HH, et al. Stereotactic body radiotherapy and checkpoint inhibitor for locally recurrent unresectable nasopharyngeal carcinoma[J]. BMJ Case Rep, 2021, 14(7): e240806.
37 Elbers JBW, Al-Mamgani A, Tesseslaar MET, et al. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: results from a phase-Ⅰ trial[J]. Radiother Oncol, 2020, 142: 79-84.
38 Biau J, Bourhis J. Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives[J]. Curr Opin Oncol, 2020, 32(3): 196-202.
39 Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929.
40 Samstein R, Rimner A, Barker CA, et al. Combined immune checkpoint blockade and radiation therapy: timing and dose fractionation associated with greatest survival duration among over 750 treated patients[J]. Int J Radiat Oncol, 2017, 99(2): S129-S130.
41 Vanpouille-Box C, Formenti SC, Demaria S. TREX1 dictates the immune fate of irradiated cancer cells[J]. Oncoimmunology, 2017, 6(9): e1339857.
[1] Liu Shiyi, Chen Zhong, Zhang Suxin. Progress in research into programmed death-1/programmed death-ligand 1 immunotherapy strategies in human papillomavirus-positive head and neck squamous cell carcinoma [J]. Int J Stomatol, 2024, 51(1): 21-27.
[2] He Zimu, Li Fenglan. Present application of digital oral positioning stents in radiotherapy of head and neck tumor [J]. Int J Stomatol, 2024, 51(1): 28-35.
[3] Yang Mingyan,Zhang Fan,Zhao Lei. Research progress on oral flora changes affecting the course of radiotherapy and chemotherapy-related oral mucositis [J]. Int J Stomatol, 2023, 50(1): 43-51.
[4] Chen Xiaoli,Zhang Fan,Liu Chengcheng. Application progress on photobiomodulation in the prevention and treatment of oral complications after radiothe-rapy [J]. Int J Stomatol, 2022, 49(6): 707-716.
[5] Wei Binbin,Hu Huiwei,Liu Yujuan,Sun Zhe,Yi Yuli. Meta-analysis and GRADE evaluation of the intervention effects of using amifostine before radiotherapy on xerostomia in patients with head and neck cancer [J]. Int J Stomatol, 2020, 47(5): 547-556.
[6] Chen Dong,Yang Zheng,Jiang Li. Research progress on the evaluation and management of radiation-induced xerostomia [J]. Int J Stomatol, 2019, 46(6): 711-717.
[7] Hao Fu,Sun Rui. Research progress on second primary carcinoma of head and neck squamous cell carcinoma [J]. Int J Stomatol, 2019, 46(5): 585-592.
[8] Zhang Xu, Xu Enxin, Ruan Min.. Correlation between Toll-like receptor 9 and head and neck squamous cell carcinoma [J]. Inter J Stomatol, 2017, 44(5): 596-601.
[9] Liu Pan1, Duolikun?Wufuer1, Cai Zhigang2, Sun Jian3. Clinical significance of serum squamous cell carcinoma antigens in Uyghur patients with oral squamous cell carcinoma [J]. Inter J Stomatol, 2016, 43(6): 645-650.
[10] Lü Danni, Li Ronglin, Yang Guangwei, Li Chunyang. Prevention and treatment of radiation- and chemotherapy-induced oral mucositis [J]. Inter J Stomatol, 2015, 42(2): 177-180.
[11] Chen Qi, Wu Yun. Therapeutic evaluation of Zhongtongan in the treatment of temporomandibular joint pain after radiotherapy [J]. Inter J Stomatol, 2015, 42(1): 24-27.
[12] Fang Juan, Song Jingjing, Ma Da, Wang Yanqiong, Zhou Fangjing, Wang Zhi. An example for the application of data-mining from Oncomine database in the research of head and neck squamous cell carcinoma [J]. Inter J Stomatol, 2014, 41(6): 647-651.
[13] WANG Ya-min, SONG Guang-bao.. The effects of radiotherapy on oral implantation [J]. Inter J Stomatol, 2011, 38(2): 204-206.
[14] HE Zhi-feng, WANG Zhi-yong, HU Qin -gang.. Research progress of dendritic cell and dendritic cell function and vaccine [J]. Inter J Stomatol, 2010, 37(6): 672-676.
[15] XIA Yong, NONG Xiao-lin. Advances in treatment of salivary gland malignant tumor [J]. Inter J Stomatol, 2009, 36(1): 46-46～49.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[7] . [J]. Foreign Med Sci: Stomatol, 2005, 32(06): 458 -460 .
[8] . [J]. Foreign Med Sci: Stomatol, 2005, 32(06): 452 -454 .
[9] . [J]. Inter J Stomatol, 2008, 35(S1): .
[10] . [J]. Inter J Stomatol, 2008, 35(S1): .